Article
A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial.
Thrombosis and haemostasis - 1 Aug 2016
Whitlock Richard P, Fordyce Christopher B, Midei Mark G, Ellis Dave, Garcia David, Weitz Jeffrey I, Canafax Daniel M, Albrecht Detlef, Milner Peter G
Abstract excerpt
Tecarfarin is a novel vitamin K antagonist that is metabolised by carboxyl estererase, thereby eliminating the variability associated with cytochrome-mediated metabolism. EmbraceAC was designed to compare the quality of anticoagulation with tecarfarin and warfarin as determined by time in therapeutic range (TTR). In this phase 2/3 randomised and blinded trial, 607 patients with indications for chronic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.